We are live on ! Find out more
CBAY

Cymabay Therapeutics
CBAY

Delisted

CBAY was delisted on the 21st of March, 2024.

Back to rankings

29 hedge funds and large institutions have $18.1M invested in Cymabay Therapeutics in 2015 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

17% less funds holding

Funds holding: 35 → 29 (-6)

21% less capital invested

Capital invested by funds: $23M → $18.1M (-$4.82M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

55% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 11

Holders
29
Holders Change
-6
Holders Change %
-17.14%
% of All Funds
0.76%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
5
Increased
7
Reduced
4
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$490K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$115K
3
Renaissance Technologies
Renaissance Technologies
New York
+$99.3K
4
KCM
Kingdon Capital Management
New York
+$71.6K
5
HF
Hoxton Financial
West Virginia
+$42.3K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$1.62M
2
GTC
Ghost Tree Capital
New York
-$776K
3
IHM
Iguana Healthcare Management
New York
-$485K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
-$107K
5
BFM
Boothbay Fund Management
New York
-$42K
Name Holding Trade Value Shares
Change 		Change in
Stake
Adage Capital Partners
1
Adage Capital Partners
Massachusetts
$2.87M – – –
A
2
Abingworth
United Kingdom
$2.67M – – –
LOAMU
3
Lombard Odier Asset Management (USA)
New York
$1.83M -$20.4K -12,517 -1%
VVM
4
Versant Venture Management
California
$1.77M – – –
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$1.75M – – –
KCM
6
Kingdon Capital Management
New York
$1.68M +$71.6K +43,920 +5%
OFM
7
Omega Fund Management
Massachusetts
$1.1M – – –
SM
8
Sabby Management
Florida
$1M +$490K +300,606 +102%
Vanguard Group
9
Vanguard Group
Pennsylvania
$843K +$115K +70,819 +17%
JGC
10
J. Goldman & Co
New York
$602K -$5.28K -3,240 -0.9%
VAM
11
Visium Asset Management
New York
$543K – – –
AllianceBernstein
12
AllianceBernstein
Tennessee
$397K – – –
PVI
13
Pura Vida Investments
New York
$338K – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$166K +$20.4K +12,500 +15%
Renaissance Technologies
15
Renaissance Technologies
New York
$103K +$99.3K +60,900 New
BFA
16
BlackRock Fund Advisors
California
$91K +$3.2K +1,961 +4%
BIT
17
BlackRock Institutional Trust
California
$78K – – –
Northern Trust
18
Northern Trust
Illinois
$51K – – –
HF
19
Hoxton Financial
West Virginia
$44K +$42.3K +25,920 New
Parallax Volatility Advisers
20
Parallax Volatility Advisers
California
$43K +$3.06K +1,874 +8%
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$43K +$41.4K +25,405 New
Bank of New York Mellon
22
Bank of New York Mellon
New York
$37K -$12.6K -7,728 -26%
ACI
23
Alpha Cubed Investments
California
$34K – – –
VKH
24
Virtu KCG Holdings
New York
$32K -$6.02K -3,694 -16%
BIM
25
BlackRock Investment Management
Delaware
$6K +$677 +415 +13%
1
2

CBAY Hedge Fund Activity: Q4 2015 in Review

29 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2015, worth a combined $18.1M — down 21% from $23M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of CBAY and 5 opened new positions — a net loss of 6 holders — while 4 trimmed existing stakes and 7 added.

The largest buyer was Sabby Management, adding an estimated $490K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.62M sold.

  • 29 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2015, down from 35 in Q3 2015.
  • Funds reported $18.1M of Cymabay Therapeutics stock for Q4 2015, down 21% quarter-over-quarter.
  • 5 funds opened new Cymabay Therapeutics positions in Q4 2015 and 11 closed out, a net change of -6 holders.
  • The largest Cymabay Therapeutics buyer in Q4 2015 was Sabby Management, an estimated $490K added.
  • The largest Cymabay Therapeutics seller in Q4 2015 was Armistice Capital, an estimated $1.62M sold.

Based on aggregated 13F filings for Q4 2015.